Aurora Cannabis Shorts Crushed as Stock Hits New High

Nelson Peltz has signed on as a strategic advisor

by Karee Venema

Published on Mar 13, 2019 at 9:48 AM

The shares of Aurora Cannabis Inc (NYSE:ACB) are trading up 11.2% at $8.89, fresh off a new per-share record high of $8.92. Boosting the weed stock is news Nelson Peltz has signed on as a strategic advisor, and will work with the cannabis company to explore possible partnerships and expand its global reach.

ACB stock is fresh off a three-day winning streak, with yesterday's 2.7% pop coming amid reports New Jersey lawmakers are paving the way to legalize recreational marijuana use. More broadly speaking, U.S.-listed ACB shares were already up 74% since hitting an five-month low of $4.58 on Dec. 24, based on last night's close at $7.96.

Short sellers have targeted the stock during its recent run higher, too, which speaks to its underlying strength. Short interest jumped 7% in the most recent reporting period to 77.13 million shares -- representing 8.3% of the equity's float, or 3.6 times the average daily pace of trading.

Options traders, on the other hand, have bought to open the March 10 call recently, with the out-of-the-money strike seeing a notable rise in open interest over the last two weeks. While some of this action was likely at the hands of traditional bulls, it's also possible short sellers are initiating an options hedge against any additional upside risk.

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

3 Million to Lose Jobs – and Not Because of Coronavirus?
A terrifying new trend can make you a millionaire or destroy your financial future.
Dell Stock Jumps on Upbeat First Quarter
DELL announced an upbeat first-quarter report
Eli Lilly Stock Soars on FDA Approval
The FDA approved Eli Lilly's Alzheimer's disease diagnostic agent
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.